Paralytic ileus
diseaseOn this page
Also known as paralytic ileus (disease)
Summary
Paralytic ileus (MONDO:0004568) is a disease and 14 clinical trials. Top therapeutic interventions include ketorolac, orphenadrine, and bupivacaine hydrochloride. A subtype of ileus — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 14
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | paralytic ileus |
| Mondo ID | MONDO:0004568 |
| DOID | DOID:8442 |
| ICD-10-CM | K56.0 |
| ICD-11 | 1868011045 |
| NCIT | C93045 |
| SNOMED CT | 55525008 |
| UMLS | C0030446 |
| MedGen | 18293 |
| Is cancer (heuristic) | no |
Also known as: paralytic ileus · paralytic ileus (disease)
Data availability: 1 HPO phenotype.
Disease family
This is a subtype of ileus. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › intestinal obstruction › ileus › paralytic ileus
Related subtypes (2): intestinal pseudo-obstruction, meconium ileus
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 14.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 6 |
| PHASE4 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE2 | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06752317 | PHASE4 | NOT_YET_RECRUITING | Effect of Preoperative Intrathecal Dexamethasone Versus Dexmedetomidine on Paralytic Ileus After Major Abdominal Surgery |
| NCT02953210 | PHASE4 | UNKNOWN | Laparoscopic Cholecystectomy: General Anesthesia With Opioid Versus General Opioid Free Anesthesia |
| NCT02958566 | PHASE4 | UNKNOWN | Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery |
| NCT01131416 | PHASE2/PHASE3 | COMPLETED | The Effects of Gum Chewing on Bowel Function Recovery Following Cesarean Section |
| NCT01389986 | PHASE2/PHASE3 | WITHDRAWN | Effects of Gum Chewing on Recovery of Bowel Function Following Abdominal Surgery for Endometrial and Ovarian Cancer |
| NCT04190173 | PHASE3 | UNKNOWN | Efficacy of PRUcalopride in Critically Ill Patients With Paralytic ILeus |
| NCT01607307 | PHASE2 | UNKNOWN | Daikenchuto for Intestinal Dysmotility and Prevention of Postoperative Paralytic Ielus After Pancreaticoduodenectomy |
| NCT03424447 | PHASE2 | UNKNOWN | Stimulation of the Efferent Loop Before Loop Ileostomy Closure |
| NCT03041675 | Not specified | UNKNOWN | Effects of Laser Acupuncture Therapy on Paralytic Ileus |
| NCT03884244 | Not specified | COMPLETED | Postoperative Chewing Gum and Gynecological Laparoscopic Surgery |
| NCT04489875 | Not specified | UNKNOWN | Gum Chewing Reduces the Risk of Postoperative Ileus After Arthroplasty Procedures in The Elderly Population |
| NCT05298774 | Not specified | COMPLETED | Myoelectric Activity Following Colorectal Surgery and Return of Bowel Function |
| NCT06113718 | Not specified | COMPLETED | The Impact of Preoperative Bowel Exercise on Postoperative Bowel Functions in Gynecologic Malignancies |
| NCT06928220 | Not specified | COMPLETED | The Impact of Manual Versus Mechanical Intestinal Suturing on the Incidence of Postoperative Complications Following Cystectomy With Ileal Conduit |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| KETOROLAC | 4 | 3 |
| ORPHENADRINE | 4 | 3 |
| BUPIVACAINE HYDROCHLORIDE | 4 | 2 |
| LIDOCAINE | 4 | 2 |
| PRUCALOPRIDE | 4 | 2 |
| CLONIDINE HYDROCHLORIDE | 4 | 1 |
| FENTANYL | 4 | 1 |
| GABAPENTIN | 4 | 1 |
| HYDROMORPHONE HYDROCHLORIDE | 4 | 1 |
| METHADONE | 4 | 1 |
| MIDAZOLAM HYDROCHLORIDE | 4 | 1 |
| MORPHINE SULFATE | 4 | 1 |
| ONDANSETRON HYDROCHLORIDE | 4 | 1 |
| RANITIDINE HYDROCHLORIDE | 4 | 1 |
| TRAMADOL | 4 | 1 |
| FIBOFLAPON SODIUM | 3 | 1 |
| CHEMBL1201111 | 0 | 1 |
| CHEMBL2096625 | 0 | 1 |
| CHEMBL4059722 | 0 | 1 |
| (R,R)-TRAMADOL | 0 | 1 |